What happened with TOMZ today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
TOMI Environmental Solutions, Inc. helps pharmaceutical manufacturers, research institutions, hospitals and food processors decontaminate their facilities. Its main offering, SteraMist, turns a hydrogen peroxide solution into an ionized mist to kill pathogens. Customers pay for equipment, the BIT Solution it consumes, and services such as decontamination work and checks that installed systems operate and perform as intended.
SteraMist accounts for most of TOMI’s revenue. As more systems are installed and used, customers consume more BIT Solution, creating repeat sales beyond the initial equipment purchase. That repeat business is not guaranteed: revenue is concentrated among a small number of customers, and significant customers have no long-term purchase commitments.
TOMI has no manufacturing facilities of its own. It relies on a single manufacturer for its SteraMist equipment line and contract manufacturers for other BIT-based systems, so interruptions can quickly prevent it from filling orders. Sales also depend on maintaining EPA registrations and suppliers meeting applicable regulatory requirements; losing a registration or a supplier’s regulatory standing could force TOMI to stop selling affected products.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
TOMI’s results hinge on SteraMist installations and recurring BIT Solution use in regulated facilities, where Steris is another hydrogen-peroxide competitor to watch beyond this list.
Ecolab’s Bioquell systems compete directly with TOMI’s SteraMist for life-sciences and healthcare customers paying for hydrogen-peroxide decontamination. Bioquell news involving these customers is more relevant to TOMI than Ecolab’s broader water and hygiene business.
Clorox’s professional and healthcare disinfectants compete with TOMI’s SteraMist for healthcare and commercial customers’ infection-control budgets, though Clorox is more consumer-focused. Watch CloroxPro and Clorox Healthcare rather than its broader consumer-product sales for the competition facing TOMI.
Ecolab, Inc. earningsECL
If Ecolab discusses Bioquell sales or placements with life-sciences and healthcare customers, its report will show whether those buyers are purchasing the hydrogen-peroxide decontamination systems that compete with TOMI's SteraMist.
Look for Ecolab's comments on Bioquell customer demand or placements, alongside its remarks on life-sciences and healthcare customers; without Bioquell-specific detail, Ecolab's broader results may not settle this question. Strong Bioquell sales or placements would show customers are adopting these systems, but also that Ecolab is competing for budgets TOMI seeks. Weak demand or slower placements would mean less pressure from Bioquell, but could also signal that these buyers are not yet widely adopting this type of system.
TOMI Environmental Solutions, Inc. earningsThis company
TOMI needs sales of SteraMist equipment, BIT Solution and services to support its operations, and this report will show whether customer demand is turning into revenue and cash.
Compare revenue and gross profit with cash used in operations. If revenue and gross profit rise while operating cash use narrows, customer purchases are doing more to support the business and pressure to raise outside capital may ease. If sales stall or fall while cash use continues, sales are not yet supporting operations and TOMI remains more reliant on financing.
